HOLD LLY
0 shares at $984.53 on 2026-05-18
Reasoning
SKIP playbook action #83. While thesis #36 (healthcare defensive) has merit and healthcare sector shows relative strength (+0.1% today), several constraints override execution: (1) Rule #14 is ACTIVE (30Y >5%)—only formation-mode defensive adds ($200-$500) with clear thesis catalysts may proceed. Playbook requests $350, which is borderline but acceptable; (2) More critically, NVDA earnings Wednesday after close is the dominant portfolio binary. Adding new positions (especially high-multiple healthcare at $1000+) immediately before NVDA's $79.2B revenue consensus binary event creates unnecessary execution risk. (3) Portfolio is already deploying $800 (GLD+XLE) from playbook—total $1,150 keeps account at ~94% cash, which is appropriate for current macro conditions. LLY is a deferred entry, not an urgent catalyst. Holding existing dry powder preserves optionality for post-NVDA volatility and post-Tuesday geopolitical clarity. If thesis #36 expires, it reflects the correct prioritization of near-term binary risks over a fourth-request formation-mode entry.